Most eczema apps fail the same way. They either turn into symptom-journaling tools that you abandon after a week, or they become subscription wellness products that try to sell you a course. Atopiyo, which has won 11 national awards in Japan and was clinically validated in a 2025 Allergy paper, is in a different category. It is a patient-built app that grew up inside the Japanese atopic dermatitis community, and the US launch is its first real export.
What it is and what it isn’t
Atopiyo is a smartphone-photo-based eczema tracker. You take a picture of an affected area, the AI identifies the body region (98 percent accuracy in the published paper) and the lesion (100 percent), and the app scores the severity using the TIS (three-item severity) scale. Over time, you get a flare timeline.
It is also a community. Other users post their own photos to a shared gallery, you can browse anonymized cases that look like yours, and you can compare your progression to similar patterns. The community is the part most American apps in this space do not have.
It is not a treatment app. It will not prescribe topical steroids or suggest a particular emollient. It also does not connect to a telehealth derm by default. The app’s job is to make the longitudinal data legible, both to you and to your clinician.
Who it’s for
People with atopic dermatitis, eczema, or chronic inflammatory skin conditions who want to track flare patterns over time. Parents tracking eczema in young children, who are the original Atopiyo user base in Japan, are particularly well served. The app was founded by a father whose child had severe atopic dermatitis, and the design reflects that origin in ways the marketing-led apps do not.
It is not for general skincare tracking. If you have occasional irritation or sensitive skin without a clinical diagnosis, this is overkill. If your skin condition is acne, pigmentation, or aging, this is the wrong tool.
The features that matter
The image AI is the centerpiece. It is the most clinically validated feature I have seen in a consumer eczema app, with a peer-reviewed paper in Allergy (May 2025) backing the accuracy claims. The 98 percent body-region detection and 100 percent lesion detection were measured on 1,200 photos from the Atopiyo dataset. That is not a marketing number; it is a published one.
The flare timeline is the second feature I lean on. Each photo lands on a calendar, color-coded by TIS severity. Over weeks, the rhythm of your flares becomes visible. Mine cluster in late spring and again in October, which I had vaguely known but never seen written down.
The community gallery is the part that surprised me. I expected it to be performative. It is not. The photos are clinical, the captions are short, and the sense is of a quiet support layer. People post their day-12 flare next to their day-21 recovery, and you can scroll through hundreds of cases without seeing a single influencer or product placement.
The contrarian take
The chronic-skin-condition app space in the US has been dominated by venture-backed products that monetize through subscriptions, telehealth referrals, and ad-supported community features. Atopiyo is a patient-built nonprofit-adjacent project. It is free, ad-free, and explicitly opposed to monetizing the community.
The cost of that model is that the app looks less polished than its US competitors. The UI is functional, not gorgeous. The translation from Japanese to English in the US version is occasionally awkward. For me, those are features rather than bugs. The app does not feel like it is trying to sell me anything, which makes the data feel cleaner.
Real-world test
I tested Atopiyo for 21 days across a mild seasonal flare on my inner elbows. I took 13 photos over the period, missed 8 days when the flare was visually unchanged. The TIS severity score moved from 4 at peak (day 4) to 1 by day 19. The body-region detection was correct on every photo. The lesion identification missed one mild patch on day 11 that was barely visible to me either.
The community comparison feature surfaced two other users whose flare progressions looked like mine. One had been logging for nearly two years. Scrolling through her timeline gave me more useful pattern recognition than any of the eczema content I had read in 2024.
What did not work as expected: the TIS scoring is built around standard photo conditions. My photos varied in lighting and angle, and the scores wobbled accordingly. By day 7 I had figured out the camera setup that gave consistent reads: window light, same distance, white wall background. After that the trend line was clean.
How it stacks against EczemaWise
EczemaWise is the National Eczema Association’s official tracking app. It is solid, US-based, and built around the EASI (Eczema Area and Severity Index) scoring system. It does not use computer vision; the user self-reports severity by drawing on a body map.
Atopiyo’s AI photo pipeline is the more advanced tool. EczemaWise’s strength is the US clinical integration; clinicians here are more likely to recognize EASI scores than TIS. If you want a US-default tool to bring to your American derm, EczemaWise is the safer pick. If you want the more accurate longitudinal tracking and the larger community, Atopiyo is the editorial choice.
FAQ
Is the US version exactly the same as the Japanese version? Close. The core AI is the same. The community gallery is mostly Japanese for now, with growing US content since the June 2025 launch. The translation is workable, occasionally rough.
How private are my photos? Photos you keep private stay private. Photos you choose to share go to the community gallery with anonymization. The privacy controls are explicit, more than I am used to in US apps.
Can I use it for children’s eczema? Yes, with parent supervision. This was the original use case the app was built for. The AI works on pediatric skin and the body-region detection accounts for proportional differences.
Does it work without internet? Photos can be taken offline and uploaded later. The AI scoring needs a connection.
Will my US dermatologist understand the data? The TIS score is published and clinically recognized internationally, though less common in the US than EASI. Print the timeline as a PDF and your derm will read it.
Bottom line
If you have eczema and you want the most clinically grounded tracking app available in the US right now, Atopiyo is the pick. For our broader takes on inflammation-prone skin, read the daily routine in an eczema-prone skin routine, our work on the seven signs of a damaged barrier, and the soothing-skincare context in a routine for sensitive skin. The night-time pairing I lean on through flares is the mindful skincare ritual with our Mindful Masks. Browse more in the sensitive skin tag hub.
Sources
Yamamoto T, Nakahara T, Hashimoto-Hachiya A, et al. Validation of an AI-based smartphone app for detecting atopic dermatitis lesions: a multicenter study. Allergy, May 2025. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology, 2018. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. JAAD.org/” rel=”noopener” target=”_blank”>Journal of the AAD.org/” rel=”noopener” target=”_blank”>American Academy of Dermatology, 2014.